Pancreatitis, which is one of the more common 'bad' Adverse Events from GLP1s, also shows up in non-GLP1-related rapid weight loss (eg extreme dieting). And shows up in diabetes trials using GLP1s, where weight loss was both slower and less total loss (because using lower dose of drug). In these diabetes GLP1 trials pancreatitis is common, but the rate of pancreatitis issues isn't big enough to ever be stat sig in a single trial.
However the lit on this is horrible - very little good data to separate 'rapidity of weight loss' from 'total weight loss'. I *suspect* it's rapidity that matters far more, but finding data to confirm it is... difficult.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.